Herpes simplex virus (HSV-1; HSV-2) (Genital herpes)

1994 ◽  
pp. 184-238
Author(s):  
Hugh Young ◽  
Marie Ogilvie
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Simplex Virus ◽  
Hsv 1

scholarly journals Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, a Novel Helicase-Primase Inhibitor

2012 ◽  
Vol 56 (7) ◽  
pp. 3587-3591 ◽  
Author(s):  
Kiyomitsu Katsumata ◽  
Adriana Weinberg ◽  
Koji Chono ◽  
Shoji Takakura ◽  
Toru Kontani ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Antiviral Agents ◽  
Term Treatment ◽  
Recurrent Genital Herpes ◽  
Short Term Treatment ◽  
Varicella Zoster ◽  
Simplex Virus ◽  
Hsv 1

ABSTRACTASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. To evaluate the anti-HSV activity of ASP2151, susceptibility testing was performed on viruses isolated from patients participating in a placebo- and valacyclovir-controlled proof-of-concept phase II study for recurrent genital herpes. A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected. ASP2151 inhibited HSV-1 and HSV-2 replication with mean 50% effective concentrations (EC50s) of 0.043 and 0.069 μM, whereas ACV exhibited mean EC50s of 2.1 and 3.2 μM, respectively. Notably, the susceptibilities of HSV isolates to ASP2151 and ACV were not altered after dosing with the antiviral agents. Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.

scholarly journals P115 Is genital herpes simplex virus type 1 (HSV-1) associated with high risk sexual behaviours?: Abstract P115 Table 1

2016 ◽  
Vol 92 (Suppl 1) ◽  
pp. A59-A60
Author(s):  
Rohilla Maarij ◽  
Sogha Khawari ◽  
Qiang Lu ◽  
Tadiwanashe Chirawu ◽  
Emily Clarke ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
High Risk ◽  
Genital Herpes ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Sexual Behaviours ◽  
Simplex Virus ◽  
Hsv 1

scholarly journals Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2

2015 ◽  
Vol 89 (16) ◽  
pp. 8219-8232 ◽  
Author(s):  
Ruchi M. Newman ◽  
Susanna L. Lamers ◽  
Brian Weiner ◽  
Stuart C. Ray ◽  
Robert C. Colgrove ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Causative Agent ◽  
The United States ◽  
Passage Number ◽  
Low Passage ◽  
Simplex Virus ◽  
Herpes Simplex Virus 2 ◽  
Hsv 1

ABSTRACTHerpes simplex virus 2 (HSV-2), the principal causative agent of recurrent genital herpes, is a highly prevalent viral infection worldwide. Limited information is available on the amount of genomic DNA variation between HSV-2 strains because only two genomes have been determined, the HG52 laboratory strain and the newly sequenced SD90e low-passage-number clinical isolate strain, each from a different geographical area. In this study, we report the nearly complete genome sequences of 34 HSV-2 low-passage-number and laboratory strains, 14 of which were collected in Uganda, 1 in South Africa, 11 in the United States, and 8 in Japan. Our analyses of these genomes demonstrated remarkable sequence conservation, regardless of geographic origin, with the maximum nucleotide divergence between strains being 0.4% across the genome. In contrast, prior studies indicated that HSV-1 genomes exhibit more sequence diversity, as well as geographical clustering. Additionally, unlike HSV-1, little viral recombination between HSV-2 strains could be substantiated. These results are interpreted in light of HSV-2 evolution, epidemiology, and pathogenesis. Finally, the newly generated sequences more closely resemble the low-passage-number SD90e than HG52, supporting the use of the former as the new reference genome of HSV-2.IMPORTANCEHerpes simplex virus 2 (HSV-2) is a causative agent of genital and neonatal herpes. Therefore, knowledge of its DNA genome and genetic variability is central to preventing and treating genital herpes. However, only two full-length HSV-2 genomes have been reported. In this study, we sequenced 34 additional HSV-2 low-passage-number and laboratory viral genomes and initiated analysis of the genetic diversity of HSV-2 strains from around the world. The analysis of these genomes will facilitate research aimed at vaccine development, diagnosis, and the evaluation of clinical manifestations and transmission of HSV-2. This information will also contribute to our understanding of HSV evolution.

scholarly journals Predeominace of Herpes Simplex Virus Type 1 from Patients with Genital Herpes in Nova Scotia

2003 ◽  
Vol 14 (2) ◽  
pp. 94-96 ◽  
Author(s):  
Kevin R Forward ◽  
Spencer HS Lee
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Relative Proportion ◽  
Sexual Practices ◽  
Simplex Virus ◽  
Hsv 1

The epidemiology of genital herpes is changing with evidence to suggest an increasing incidence of herpes simplex virus type 1 (HSV-1) infections. The results of 6529 HSV genital cultures taken between April 1998 and December 2001 were reviewed. Overall, HSV-1 was recovered more often than HSV-2; 1213 versus 1045. This trend was particularly striking in young women 30 years of age or less, in whom 70.8% of isolates were HSV-1. In men of the same age range, 45% of isolates were HSV-1. The proportion of women with HSV-1 declined from 73.7% in those younger than 31 years of age to 4.5% in those older than 60 years of age.These observations have important implications. The decline in the relative proportion of HSV-1 isolates from young adults may be the result of changing sexual practices, changing susceptibility or increased exposure to HSV-1 during vaginal intercourse. In this setting HSV-2 vaccines may be less likely to produce the desired reduction in the overall prevalence of genital herpes infections.

scholarly journals Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions

2020 ◽  
Vol 5 (7) ◽  
pp. e002388 ◽  
Author(s):  
Wajiha Yousuf ◽  
Hania Ibrahim ◽  
Manale Harfouche ◽  
Farah Abu Hijleh ◽  
Laith Abu-Raddad
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Genital Herpes ◽  
Virus Type ◽  
Herpes Simplex Virus Type ◽  
Sexual Debut ◽  
Simplex Virus ◽  
Meta Analyses ◽  
Hsv 1

ObjectiveTo describe the epidemiology of herpes simplex virus type 1 (HSV-1) in Europe.MethodsWe systematically reviewed HSV-1 related publications, conducted various meta-analyses and meta-regressions, assessed pooled mean seroprevalence, and estimated pooled mean proportions of HSV-1 viral detection in clinically diagnosed genital ulcer disease (GUD) and in genital herpes.ResultsWe extracted, from 142 relevant records, 179 overall (622 stratified) seroprevalence measures, 4 overall proportions of HSV-1 in GUD and 64 overall (162 stratified) proportions of HSV-1 in genital herpes. Pooled mean seroprevalence was 67.4% (95% CI 65.5% to 69.3%) with 32.5% (95% CI 29.4% to 35.7%) of children and 74.4% (95% CI 72.8% to 76.0%) of adults infected. Pooled seroprevalence increased steadily with age, being lowest in those aged <20 years (39.3%, 95% CI 35.9% to 42.7%) and highest in those aged >50 years (82.9%, 95% CI 78.8% to 86.6%). Pooled seroprevalence decreased yearly by 0.99-fold (95% CI 0.99 to 1.00). Pooled mean proportion of HSV-1 detection was 13.6% (95% CI 4.1% to 27.1%) in GUD, 34.1% (95% CI 31.7% to 36.5%) in genital herpes and 49.3% (95% CI 42.2% to 56.4%) in first episode genital herpes. Pooled proportion of HSV-1 detection in genital herpes increased yearly by 1.01-fold (95% CI 1.00 to 1.02), with higher detection in women (42.0%, 95% CI 37.4% to 46.7%) than men (24.1%, 95% CI 19.8% to 28.6%).ConclusionsHSV-1 epidemiology is transitioning away from its historical pattern of oral acquisition in childhood. Every year, seroprevalence is declining by 1% and the proportion of HSV-1 in genital herpes is increasing by 1%. As many as two-thirds of children are reaching sexual debut unexposed, and at risk of HSV-1 genital acquisition in adulthood.

Sign in / Sign up

Export Citation Format

Share Document